SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves’ disease
- 9 June 2021
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 73 (2) , 243-254
Abstract
Coronavirus disease 2019 (COVID-19) advances to affect every part of the globe and remains a challenge to the human race. Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was shown to affect many organs and organ systems including the thyroid gland as these parts highly express angiotensin-converting enzyme 2 (ACE2) protein, which functions as a receptor for initially entering the virus into the cells. Furthermore, some categories of the population including older people and persons with comorbidities are prone to be more vulnerable to COVID-19 and its complications. Recent reports showed that SARS-CoV-2 infection could cause Graves’ disease (autoimmune hyperthyroidism) in post-COVID-19 patients. Factors that may boost the mortality risk of COVID-19 patients are not completely known yet and a clear perception of the group of vulnerable people is also essential. This review briefly summarizes the features of Graves’ disease such as symptoms, risk factors, including environmental, genetic, immunological, and other factors, associated disorders, and therapeutic options. It comprehensively describes the recent advances in SARS-CoV-2-induced Graves’ disease and the pivotal role of autoimmune factors in inducing the disease. The review also discusses the possible risks of SARS-CoV-2 infection and associated COVID-19 in people with hyperthyroidism. Furthermore, it explains thyroid disease and its association with the severity of COVID-19.Keywords
This publication has 68 references indexed in Scilit:
- Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritisProceedings of the National Academy of Sciences, 2008
- Autoimmune disease after autologous hematopoietic stem cell transplantationAutoimmunity Reviews, 2008
- The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune diseaseClinical and Experimental Immunology, 2007
- The Role of Stress in the Clinical Expression of Thyroid AutoimmunityAnnals of the New York Academy of Sciences, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppressionEuropean Journal of Endocrinology, 2006
- Autoimmune thyroid disease: new models of cell death in autoimmunityNature Reviews Immunology, 2002
- T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.Journal of Experimental Medicine, 1996
- Evidence for selective accumulation of intrathyroidal T lymphocytes in human autoimmune thyroid disease based on T cell receptor V gene usage.Journal of Clinical Investigation, 1992
- Evidence of Limited Variability of Antigen Receptors on Intrathyroidal T Cells in Autoimmune Thyroid DiseaseNew England Journal of Medicine, 1991